NEW YORK, NY / ACCESSWIRE / June 11, 2018 / Acorda Therapeutics was seeing big gains on Friday after Wall Street learned that the company's lawyers had try to save previously invalidated patents for its key multiple sclerosis drug Ampyra. Shares of TrovaGene saw big losses after the company announced an underwritten public offering last week of 18 million shares.

RDI Initiates Coverage on:

Acorda Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=ACOR

TrovaGene, Inc.
https://rdinvesting.com/news/?ticker=TROV

Acorda Therapeutics, Inc. shares closed up almost 9% on about 5.7 million shares this past Friday. The stock hit a new high of $36.35 that day with shares even gaining as much as 30%. It was last Thursday that the company's lawyers had made arguments in front of a panel at the U.S. Court of Appeals for the Federal Circuit, responding to an earlier decision made by the U.S. District Court to invalidate four of the company's patents for its multiple sclerosis drug Ampyra. It was at the beginning of May that the company had posted first quarter results, revealing a GAAP net loss of $8.2 million. Adjusted earnings were 14 cents a share, falling very short of the 73 cents that analysts had expected. Revenue of $106.2 million was also behind the $125.7 million that analysts expected.

Access RDI's Acorda Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ACOR

TrovaGene, Inc. collapsed on Friday, closing the day down 48% on skyrocket trading volume compared to usual. The stock hit a new low of 79 cents during intra-day trading. It was on Thursday that the company announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock and common stock warrants to purchase up to an aggregate of 18,000,000 shares of common stock. The clinical-stage oncology therapeutics company also went through a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12, effective June 1. Trovagene has intellectual property and proprietary technology that enables it to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies.

Access RDI's TrovaGene, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TROV

Our Actionable Research on Acorda Therapeutics, Inc. (NASDAQ: ACOR) and TrovaGene, Inc. (NASDAQ: TROV) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com